Received: 18 December 2020
Accepted: 3 June 2021
First Online: 7 June 2021
: This study, including the procedure for enrollment, was approved by the institutional review board of each participating facility, including the official institutional review board committee of Osaka University Hospital (approved on February 24, 2016). Written informed consent, including data publication, was received from each participating patient.
: Daisaku Nakatani has received honoraria from Roche Diagnostics. Shungo Hikoso has received personal fees from Daiichi Sankyo Company, Bayer, Astellas Pharma, Pfizer Pharmaceuticals and Boehringer Ingelheim Japan, and received grants from Roche Diagnostics, FUJIFILM Toyama Chemical and Actelion Pharmaceuticals. Yasushi Sakata received personal fees from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation and Actelion Pharmaceuticals, and received grants form Roche Diagnostic, FUJIFILM Toyama Chemical, Abbott Medical Japan, Otsuka Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation and Biotronik. Other authors have no conflicts of interest to disclose.